Leaders in Medical Device Preclinical Research Join Forces as Surpass Acquires LyChron

January 17, 2017

Surpass and Surpass-Silicon Valley, LLC (formerly LyChron, LLC) to offer premier preclinical research services, accelerating progress along the product development pipeline.

Osceola, WI - Surpass, Inc. ("Surpass") announced today the acquisition of LyChron, LLC ("LyChron"), expanding its capacity to serve the medical device and preclinical research community. The new California entity will operate as Surpass-Silicon Valley, LLC.

Liann Johnson, President & CEO of Surpass, expressed her confidence in bringing the two companies together. "Given significant synergies in the core competencies of each organization, we now have the opportunity to identify best practices and implement them across the standard operating procedures to assure that our clients receive the highest quality preclinical study experience available today."

The operating environment for Contract Research Organizations has become increasingly challenging. Johnson continued, "Globally we are facing a strained economic landscape, and our clients, medical device and biopharmaceutical companies, are dealing with regulatory uncertainties and profit erosion." As a result of the acquisition, Surpass' and LyChron's clients will benefit by leveraging the combined resources, capacity and expertise of the organizations from the earliest feasibility/proof-of-concept to pivotal GLP-compliant studies.

About LyChron

LyChron was founded in 2000 by a team of scientists and physicians and provides proof-of-concept, feasibility, prototype evaluation, validation, and GLP safety preclinical studies, as well as facilitating physician and clinical training, refining study designs, and developing novel disease models. Located in Mountain View, CA, LyChron is experienced with the evaluation of medical devices, gene or cell therapies, and pharmacological agents intended for human and veterinary clinical trials and ultimate market release.

About Surpass

A recognized leader in preclinical research, Surpass provides comprehensive services for the development, characterization, and evaluation of medical devices, pharmaceuticals, biologics, and combination products with extensive expertise in surgical and interventional procedures. Experienced professionals, state-of-the-art facilities with advanced equipment, and proven methods make Surpass a trusted partner and lab of choice for preclinical feasibility, product development, pivotal GLP safety, and physician training studies.

Surpass has a breadth of case experience in preclinical studies including feasibility and safety assessments of ablation systems, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, pharmaceuticals, imaging systems, cardiac assist devices, and more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful.

Connect with Surpass, Inc. on Linked InYouTubeTwitterFacebook, and Google+